Changchun High-Tech Industries announced that the clinical trial application for the type II herpes simplex virus mRNA vaccine of its holding subsidiary has been approved.
长春高新：控股子公司Ⅱ型单纯疱疹病毒mRNA疫苗临床试验申请获得批准
Changchun High-Tech Industries: The clinical trial application for the type II herpes simplex virus mRNA vaccine of its holding subsidiary has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated